#BEGIN_DRUGCARD DB03345

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
60-24-2

# ChEBI_ID:
41218

# Chemical_Formula:
C2H6OS

# Chemical_IUPAC_Name:
2-sulfanylethan-1-ol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
1E+006 mg/L

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Beta-Mercaptoethanol

# HET_ID:
SEO

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C2H6OS/c3-1-2-4/h3-4H,1-2H2

# InChI_Key:
InChIKey=DGVVWUTYPXICAM-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
C00928

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3345

# Mechanism_Of_Action:
Not Available

# Melting_Point:
< 25 °C

# Molecular_Weight_Avg:
78.133

# Molecular_Weight_Mono:
78.013935504

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1QMJ

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
0.11

# Predicted_LogS:
-0.43

# Predicted_Water_Solubility:
2.92e+01 g/l

# Primary_Accession_No:
DB03345

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
1567

# PubChem_Substance_ID:
46506852

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
DB03131
EXPT02882

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OCCS

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
2-Sulfhydryl-Ethanol

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:09 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
9.72 (at 25 °C)

# Drug_Target_10_Cellular_Location:
Cytoplasmic

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
Not Available

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
Not Available

# Drug_Target_10_GenBank_ID_Gene:
AE000511

# Drug_Target_10_GenBank_ID_Protein:
Not Available

# Drug_Target_10_GeneCard_ID:
Not Available

# Drug_Target_10_Gene_Name:
HP_0602

# Drug_Target_10_Gene_Sequence:
>657 bp
GTGTTGGATAGTTTTGAGATTTTAAAGGCTTTAAAGAGCTTGGATTTATTGAAAAACGCC
CCTAGTTGGTGGTGGCCTAACGCTTTGAAATTTGAAGCTTTATTAGGGGCGGTTTTAACG
CAAAATACTAAATTTGAAGCCGTTTTGAAATCTTTAGAAAATTTAAAAAACGCTTTCATT
TTAGAAAATGATGATGAGATCAATCTTAAAAAAATCGCTTATATAGAGTTTTCAAAGCTT
GCAGAGTGTGTCCGCCCTAGCGGGTTTTATAACCAAAAAGCCAAACGACTGATTGATTTG
AGTAAGAATATTTTAAAAGACTTTCAAAGTTTTGAAAATTTTAAACAAGAAGTAACCAGA
GAGTGGCTTTTAAACCAAAAGGGCGTTGGCAAAGAAAGCGCGGATGCGATTTTATGCTAT
GTGTGCGCTAAAGAAGTGATGGTGGTGGATAAATATAGCTATCTTTTTTTAAAAAAAATA
GGCATAGAGATAGAAGATTATGACGAATTGCAACATTTTTTTGAAAAAGGCGTTCAAGAG
AATTTAAATTCCGCCTTAGCGCTTTATGAAAACACCATTCCTTTAGCGCAACTTTATGCG
AGATTCCATGGAAAGATCGTAGAATTTTCCAAACAAAAATTGGAATTAAAACTTTGA

# Drug_Target_10_General_Function:
Involved in catalytic activity

# Drug_Target_10_General_References:
14517230	Eichman BF, O'Rourke EJ, Radicella JP, Ellenberger T: Crystal structures of 3-methyladenine DNA glycosylase MagIII and the recognition of alkylated bases. EMBO J. 2003 Oct 1;22(19):4898-909.
9252185	Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischmann RD, Ketchum KA, Klenk HP, Gill S, Dougherty BA, Nelson K, Quackenbush J, Zhou L, Kirkness EF, Peterson S, Loftus B, Richardson D, Dodson R, Khalak HG, Glodek A, McKenney K, Fitzegerald LM, Lee N, Adams MD, Hickey EK, Berg DE, Gocayne JD, Utterback TR, Peterson JD, Kelley JM, Cotton MD, Weidman JM, Fujii C, Bowman C, Watthey L, Wallin E, Hayes WS, Borodovsky M, Karp PD, Smith HO, Fraser CM, Venter JC: The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature. 1997 Aug 7;388(6642):539-47.

# Drug_Target_10_HGNC_ID:
Not Available

# Drug_Target_10_HPRD_ID:
Not Available

# Drug_Target_10_ID:
4549

# Drug_Target_10_Locus:
Not Available

# Drug_Target_10_Molecular_Weight:
25287

# Drug_Target_10_Name:
Endonuclease III

# Drug_Target_10_Number_of_Residues:
218

# Drug_Target_10_PDB_ID:
1PU7

# Drug_Target_10_Pathway:
Not Available

# Drug_Target_10_Pfam_Domain_Function:
PF00633	HHH
PF00730	HhH-GPD

# Drug_Target_10_Protein_Sequence:
>Endonuclease III
MLDSFEILKALKSLDLLKNAPSWWWPNALKFEALLGAVLTQNTKFEAVLKSLENLKNAFI
LENDDEINLKKIAYIEFSKLAECVRPSGFYNQKAKRLIDLSKNILKDFQSFENFKQEVTR
EWLLNQKGVGKESADAILCYVCAKEVMVVDKYSYLFLKKIGIEIEDYDELQHFFEKGVQE
NLNSALALYENTIPLAQLYARFHGKIVEFSKQKLELKL

# Drug_Target_10_Reaction:
Not Available

# Drug_Target_10_Signals:
None

# Drug_Target_10_Specific_Function:
Not Available

# Drug_Target_10_SwissProt_ID:
O25323

# Drug_Target_10_SwissProt_Name:
O25323_HELPY

# Drug_Target_10_Synonyms:
Not Available

# Drug_Target_10_Theoretical_pI:
6.55

# Drug_Target_10_Transmembrane_Regions:
None

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X04567

# Drug_Target_1_GenBank_ID_Protein:
15261

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
E

# Drug_Target_1_Gene_Sequence:
>495 bp
ATGAATATATTTGAAATGTTACGTATAGATGAACGTCTTAGACTTAAAATCTATAAAGAC
ACAGAAGGCTATTACACTATTGGCATCGGTCATTTGCTTACAAAAAGTCCATCACTTAAT
GCTGCTAAATCTGAATTAGATAAAGCTATTGGGCGTAATTGCAATGGTGTAATTACAAAA
GATGAGGCTGAAAAACTCTTTAATCAGGATGTTGATGCTGCTGTTCGCGGAATTCTGAGA
AATGCTAAATTAAAACCGGTTTATGATTCTCTTGATGCGGTTCGTCGCTGTGCATTGATT
AATATGGTTTTCCAAATGGGAGAAACCGGTGTGGCAGGATTTACTAACTCTTTACGTATG
CTTCAACAAAAACGCTGGGATGAAGCAGCAGTTAACTTAGCTAAAAGTATATGGTATAAT
CAAACACCTAATCGCGCAAAACGAGTCATTACAACGTTTAGAACTGGCACTTGGGACGCG
TATAAAAATCTATAA

# Drug_Target_1_General_Function:
Involved in lysozyme activity

# Drug_Target_1_General_References:
12626685	Miller ES, Kutter E, Mosig G, Arisaka F, Kunisawa T, Ruger W: Bacteriophage T4 genome. Microbiol Mol Biol Rev. 2003 Mar;67(1):86-156, table of contents.
1731252	Eriksson AE, Baase WA, Wozniak JA, Matthews BW: A cavity-containing mutant of T4 lysozyme is stabilized by buried benzene. Nature. 1992 Jan 23;355(6358):371-3.
2207079	McIntosh LP, Wand AJ, Lowry DF, Redfield AG, Dahlquist FW: Assignment of the backbone 1H and 15N NMR resonances of bacteriophage T4 lysozyme. Biochemistry. 1990 Jul 10;29(27):6341-62.
2234094	Faber HR, Matthews BW: A mutant T4 lysozyme displays five different crystal conformations. Nature. 1990 Nov 15;348(6298):263-6.
3024113	Valerie K, Stevens J, Lynch M, Henderson EE, de Riel JK: Nucleotide sequence and analysis of the 58.3 to 65.5-kb early region of bacteriophage T4. Nucleic Acids Res. 1986 Nov 11;14(21):8637-54.
322662	Remington SJ, Eyck LF, Matthews BW: Atomic coordinates for T4 phage lysozyme. Biochem Biophys Res Commun. 1977 Mar 21;75(2):265-70.
3405287	Matsumura M, Becktel WJ, Matthews BW: Hydrophobic stabilization in T4 lysozyme determined directly by multiple substitutions of Ile 3. Nature. 1988 Aug 4;334(6181):406-10.
3586019	Weaver LH, Matthews BW: Structure of bacteriophage T4 lysozyme refined at 1.7 A resolution. J Mol Biol. 1987 Jan 5;193(1):189-99.
4530293	Matthews BW, Remington SJ: The three dimensional structure of the lysozyme from bacteriophage T4. Proc Natl Acad Sci U S A. 1974 Oct;71(10):4178-82.
5470817	Inouye M, Imada M, Tsugita A: The amino acid sequence of T4 phage lysozyme. IV. Dilute acid hydrolysis and the order of tryptic peptides. J Biol Chem. 1970 Jul 25;245(14):3479-84.
6302287	Owen JE, Schultz DW, Taylor A, Smith GR: Nucleotide sequence of the lysozyme gene of bacteriophage T4. Analysis of mutations involving repeated sequences. J Mol Biol. 1983 Apr 5;165(2):229-48.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2300

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
18636

# Drug_Target_1_Name:
Lysozyme

# Drug_Target_1_Number_of_Residues:
164

# Drug_Target_1_PDB_ID:
7LZM

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00959	Phage_lysozyme

# Drug_Target_1_Protein_Sequence:
>Lysozyme
MNIFEMLRIDEGLRLKIYKDTEGYYTIGIGHLLTKSPSLNAAKSELDKAIGRNCNGVITK
DEAEKLFNQDVDAAVRGILRNAKLKPVYDSLDAVRRCALINMVFQMGETGVAGFTNSLRM
LQQKRWDEAAVNLAKSRWYNQTPNRAKRVITTFRTGTWDAYKNL

# Drug_Target_1_Reaction:
Hydrolysis of 1,4-beta-linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in a peptidoglycan and between N-acetyl-D-glucosamine residues in chitodextrins

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Helps to release the mature phage particles from the cell wall by breaking down the peptidoglycan

# Drug_Target_1_SwissProt_ID:
P00720

# Drug_Target_1_SwissProt_Name:
LYS_BPT4

# Drug_Target_1_Synonyms:
EC 3.2.1.17
Endolysin
Lysis protein
Muramidase

# Drug_Target_1_Theoretical_pI:
10.08

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
GLO1

# Drug_Target_2_GenBank_ID_Gene:
D13315

# Drug_Target_2_GenBank_ID_Protein:
219664

# Drug_Target_2_GeneCard_ID:
GLO1

# Drug_Target_2_Gene_Name:
GLO1

# Drug_Target_2_Gene_Sequence:
>555 bp
ATGGCAGAACCGCAGCCCCCGTCCGGCGGCCTCACGGACGAGGCCGCCCTCAGTTGCTGC
TCCGACGCGGACCCCAGTACCAAGGATTTTCTATTGCAGCAGACCATGCTACGAGTGAAG
GATCCTAAGAAGTCACTGGATTTTTATACTAGAGTTCTTGGAATGACGCTAATCCAAAAA
TGTGATTTTCCCATTATGAAGTTTTCACTCTACTTCTTGGCTTATGAGGATAAAAATGAC
ATCCCTAAAGAAAAAGATGAAAAAATAGCCTGGGCGCTCTCCAGAAAAGCTACACTTGAG
CTGACACACAATTGGGGCACTGAAGATGATGCGACCCAGAGTTACCACAATGGCAATTCA
GACCCTCGAGGATTCGGTCATATTGGAATTGCTGTTCCTGATGTATACAGTGCTTGTAAA
AGGTTTGAAGAACTGGGAGTCAAATTTGTGAAGAAACCTGATGATGGTAAAATGAAAGGC
CTGGCATTTATTCAAGATCCTGATGGCTACTGGATTGAAATTTTGAATCCTAACAAAATG
GCAACCTTAATGTAG

# Drug_Target_2_General_Function:
Amino acid transport and metabolism

# Drug_Target_2_General_References:
10521255	Cameron AD, Ridderstrom M, Olin B, Kavarana MJ, Creighton DJ, Mannervik B: Reaction mechanism of glyoxalase I explored by an X-ray crystallographic analysis of the human enzyme in complex with a transition state analogue. Biochemistry. 1999 Oct 12;38(41):13480-90.
10564821	Ranganathan S, Ciaccio PJ, Walsh ES, Tew KD: Genomic sequence of human glyoxalase-I: analysis of promoter activity and its regulation. Gene. 1999 Nov 15;240(1):149-55.
14574404	Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6. Nature. 2003 Oct 23;425(6960):805-11.
7684374	Kim NS, Umezawa Y, Ohmura S, Kato S: Human glyoxalase I. cDNA cloning, expression, and sequence similarity to glyoxalase I from Pseudomonas putida. J Biol Chem. 1993 May 25;268(15):11217-21.
8449929	Ranganathan S, Walsh ES, Godwin AK, Tew KD: Cloning and characterization of human colon glyoxalase-I. J Biol Chem. 1993 Mar 15;268(8):5661-7.
8670058	Ridderstrom M, Mannervik B: Optimized heterologous expression of the human zinc enzyme glyoxalase I. Biochem J. 1996 Mar 1;314 ( Pt 2):463-7.
9218781	Cameron AD, Olin B, Ridderstrom M, Mannervik B, Jones TA: Crystal structure of human glyoxalase I--evidence for gene duplication and 3D domain swapping. EMBO J. 1997 Jun 16;16(12):3386-95.
9705294	Ridderstrom M, Cameron AD, Jones TA, Mannervik B: Involvement of an active-site Zn2+ ligand in the catalytic mechanism of human glyoxalase I. J Biol Chem. 1998 Aug 21;273(34):21623-8.

# Drug_Target_2_HGNC_ID:
HGNC:4323

# Drug_Target_2_HPRD_ID:
00730

# Drug_Target_2_ID:
1313

# Drug_Target_2_Locus:
6p21.3-p21.1

# Drug_Target_2_Molecular_Weight:
20778

# Drug_Target_2_Name:
Lactoylglutathione lyase

# Drug_Target_2_Number_of_Residues:
184

# Drug_Target_2_PDB_ID:
1QIP

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00903	Glyoxalase

# Drug_Target_2_Protein_Sequence:
>Lactoylglutathione lyase
MAEPQPPSGGLTDEAALSCCSDADPSTKDFLLQQTMLRVKDPKKSLDFYTRVLGMTLIQK
CDFPIMKFSLYFLAYEDKNDIPKEKDEKIAWALSRKATLELTHNWGTEDDETQSYHNGNS
DPRGFGHIGIAVPDVYSACKRFEELGVKFVKKPDDGKMKGLAFIQDPDGYWIEILNPNKM
ATLM

# Drug_Target_2_Reaction:
(R)-S-lactoylglutathione = glutathione + methylglyoxal

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Catalyzes the conversion of hemimercaptal, formed from methylglyoxal and glutathione, to S-lactoylglutathione

# Drug_Target_2_SwissProt_ID:
Q04760

# Drug_Target_2_SwissProt_Name:
LGUL_HUMAN

# Drug_Target_2_Synonyms:
Aldoketomutase
EC 4.4.1.5
Glx I
Glyoxalase I
Ketone-aldehyde mutase
Methylglyoxalase
S-D- lactoylglutathione methylglyoxal lyase

# Drug_Target_2_Theoretical_pI:
4.92

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
PNPO

# Drug_Target_3_GenBank_ID_Gene:
AF468030

# Drug_Target_3_GenBank_ID_Protein:
21728336

# Drug_Target_3_GeneCard_ID:
PNPO

# Drug_Target_3_Gene_Name:
PNPO

# Drug_Target_3_Gene_Sequence:
>786 bp
ATGACGTGCTGGCTGCGGGGCGTCACGGCGACGTTCGGGCGACCTGCCGAGTGGCCAGGC
TACCTCAGTCACCTGTGTGGTCGCAGTGCTGCCATGGACCTGGGACCCATGCGCAAGAGT
TACCGCGGGGACCGAGAGGCATTTGAGGAGACTCATCTGACCTCCCTTGACCCAGTGAAA
CAGTTTGCTGCCTGGTTTGAGGAGGCTGTTCAGTGTCCTGACATAGGGGAAGCCAATGCC
ATGTGTCTGGCTACCTGCACCAGAGATGGAAAACCCTCTGCTCGCATGTTGCTGCTGAAG
GGCTTCGGGAAAGATGGCTTCCGCTTCTTCACTAACTTCGAGAGTCGAAAAGGAAAAGAG
CTGGACTCTAATCCCTTTGCTTCCCTTGTCTTCTACTGGGAGCCACTTAACCGTCAGGTG
CGTGTGGAAGGCCCTGTGAAGAAACTGCCTGAGGAGGAGGCTGAGTGCTACTTCCACTCC
CGCCCCAAGAGCAGCCAGATTGGGGCTGTGGTCAGCCACCAGAGTTCTGTGATCCCTGAT
CGGGAGTATCTGAGAAAGAAAAATGAGGAACTGGAACAGCTCTACCAGGATCAAGAGGTG
CCCAAGCCAAAATCCTGGGGTGGCTATGTCCTGTACCCTCAGGTGATGGAGTTCTGGCAA
GGTCAAACCAACCGCCTGCATGACCGGATAGTCTTTCGGCGGGGCCTACCCACAGGAGAT
TCCCCTTTGGGGCCCATGACCCACCGCGGGGAGGAAGACTGGCTCTATGAGAGACTTGCA
CCTTAA

# Drug_Target_3_General_Function:
Coenzyme transport and metabolism

# Drug_Target_3_General_References:
12824491	Musayev FN, Di Salvo ML, Ko TP, Schirch V, Safo MK: Structure and properties of recombinant human pyridoxine 5'-phosphate oxidase. Protein Sci. 2003 Jul;12(7):1455-63.

# Drug_Target_3_HGNC_ID:
HGNC:30260

# Drug_Target_3_HPRD_ID:
04476

# Drug_Target_3_ID:
203

# Drug_Target_3_Locus:
17q21.32

# Drug_Target_3_Molecular_Weight:
29988

# Drug_Target_3_Name:
Pyridoxine-5'-phosphate oxidase

# Drug_Target_3_Number_of_Residues:
261

# Drug_Target_3_PDB_ID:
1NRG

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF01243	Pyridox_oxidase

# Drug_Target_3_Protein_Sequence:
>Pyridoxine-5'-phosphate oxidase
MTCWLRGVTATFGRPAEWPGYLSHLCGRSAAMDLGPMRKSYRGDREAFEETHLTSLDPVK
QFAAWFEEAVQCPDIGEANAMCLATCTRDGKPSARMLLLKGFGKDGFRFFTNFESRKGKE
LDSNPFASLVFYWEPLNRQVRVEGPVKKLPEEEAECYFHSRPKSSQIGAVVSHQSSVIPD
REYLRKKNEELEQLYQDQEVPKPKSWGGYVLYPQVMEFWQGQTNRLHDRIVFRRGLPTGD
SPLGPMTHRGEEDWLYERLAP

# Drug_Target_3_Reaction:
(1) pyridoxamine 5'-phosphate + H2O + O2 = pyridoxal 5'-phosphate + NH3 + H2O2

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Oxidizes PNP and PMP into pyridoxal 5'-phosphate (PLP)

# Drug_Target_3_SwissProt_ID:
Q9NVS9

# Drug_Target_3_SwissProt_Name:
PNPO_HUMAN

# Drug_Target_3_Synonyms:
EC 1.4.3.5
Pyridoxamine-phosphate oxidase

# Drug_Target_3_Theoretical_pI:
7.09

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Periplasm

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
M97379

# Drug_Target_4_GenBank_ID_Protein:
155588

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
gfo

# Drug_Target_4_Gene_Sequence:
>1320 bp
ATGACGAACAAAATCTCGTCTTCAGATAATCTTTCCAATGCTGTTTCAGCAACGGATGAC
AACGCTTCCCGTACGCCAAATCTGAACCGTCGCGCTCTCGTTGGTGGTGGTGTTGGACTG
GCCGCACGTGGCGCCTTAGCCAGTGGTCTTCAGGCAGCGACGCTTCCTGCTGGTGCCAGC
CTGGTTCCGACCACGCCTGCAGGTCGCCCGATGCCTTACGCGATCCGCCCGATGCCGGAA
GATCGTCGTTTCGGTTATGCTATCGTCGGTCTGGGTAAATATGCCCTTAACCAGATTTTA
CCGGGTTTTGCCGGATGCCAGCATTCCCGCATGAAGCTTTGGTCAGCGGTAACCGAAAAA
GCTAAAATCGTTGCCGCTGAATATGGCGTCGATCCCCGTAAAATTTATGATTACAGCAAC
TTCGACAAGATCGCTAAAGATCCAAAAATCGACGCTGTTTACATCATTTTGCCAAACTCT
TTGCATGCTGAATTTGCTATCCGTTCTTTCAAAGCCGGCAAGCATGTTATGTGTGAAAAG
CCGATGGCAACCTCTGTTGCTGATTGTCAGCGGATGATCGATGCAGCCAAGGCTGCTAAT
AAAAAGCTGATGATCGGTTACCGTTGCCACTATGATCCAATGAACCGTGCAGCGGTAAAA
TTGATCCGTGAAAACCAGTTGGGTAAACTGGGCATGGTTACCACCGACAACTCAGACGTT
ATGGATCAGAACGACCTGCACAGCAGTGGCGTCTGCGTCGTGAACTCCGGTGGCGGTTCT
TTGATGGATATCGGTATTTATGGCTTGAACGGTACCCGTTACTTGCTGGGTGAAGAACCG
ATCGAAGTCCGTGCTTACACCTACAGCGATCCGAATGATGAACGTTTCGTTGAAGTCGAA
GATCGTATTATTTGGCAGATGCGCTTCAGAAGCGGTGCTCTGTCTCATGGTGCATCTTCT
TATTCGACCACGACGACTTCACGTTTCTCGGTGCAGGGCGACAAAGCTGTTCTGTTGATG
GATCCGGCTACCGGATATTATCAGAATTTGATTTCTGTCCAGACCCCAGGCCATGCTAAC
CAGTCGATGATGCCACAGTTCATCATGCCAGCGAACAACCAGTTCTCTGCACAGTTGGAT
CATCTGGCTGAAGCCGTCATCAATAACAAACCAGTTCGTAGCCCGGGTGAAGAAGGTATG
CAGGATGTGCGCCTGATTCAGGCCATTTATGAAGCAGCTCGTACCGGTCGCGCCGTCAAC
ACGGATTGGGGTTATGTGCGTCAGGTGGTTATTGATTCTGACTTAACCTATTTGGGTTAA

# Drug_Target_4_General_Function:
Involved in oxidoreductase activity

# Drug_Target_4_General_References:
1537789	Kanagasundaram V, Scopes RK: Cloning, sequence analysis, and expression of the structural gene encoding glucose-fructose oxidoreductase from Zymomonas mobilis. J Bacteriol. 1992 Mar;174(5):1439-47.
8472911	Loos H, Sahm H, Sprenger GA: Glucose-fructose oxidoreductase, a periplasmic enzyme of Zymomonas mobilis, is active in its precursor form. FEMS Microbiol Lett. 1993 Mar 1;107(2-3):293-8.
8994968	Kingston RL, Scopes RK, Baker EN: The structure of glucose-fructose oxidoreductase from Zymomonas mobilis: an osmoprotective periplasmic enzyme containing non-dissociable NADP. Structure. 1996 Dec 15;4(12):1413-28.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
2826

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
47190

# Drug_Target_4_Name:
Glucose--fructose oxidoreductase

# Drug_Target_4_Number_of_Residues:
433

# Drug_Target_4_PDB_ID:
1H6A

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF01408	GFO_IDH_MocA
PF02894	GFO_IDH_MocA_C

# Drug_Target_4_Protein_Sequence:
>Glucose--fructose oxidoreductase precursor
MTNKISSSDNLSNAVSATDDNASRTPNLTRRALVGGGVGLAAAGALASGLQAATLPAGAS
QVPTTPAGRPMPYAIRPMPEDRRFGYAIVGLGKYALNQILPGFAGCQHSRIEALVSGNAE
KAKIVAAEYGVDPRKIYDYSNFDKIAKDPKIDAVYIILPNSLHAEFAIRAFKAGKHVMCE
KPMATSVADCQRMIDAAKAANKKLMIGYRCHYDPMNRAAVKLIRENQLGKLGMVTTDNSD
VMDQNDPAQQWRLRRELAGGGSLMDIGIYGLNGTRYLLGEEPIEVRAYTYSDPNDERFVE
VEDRIIWQMRFRSGALSHGASSYSTTTTSRFSVQGDKAVLLMDPATGYYQNLISVQTPGH
ANQSMMPQFIMPANNQFSAQLDHLAEAVINNKPVRSPGEEGMQDVRLIQAIYEAARTGRP
VNTDWGYVRQGGY

# Drug_Target_4_Reaction:
D-glucose + D-fructose = D-gluconolactone + D-glucitol

# Drug_Target_4_Signals:
1-52

# Drug_Target_4_Specific_Function:
D-glucose + D-fructose = D-gluconolactone + D- glucitol

# Drug_Target_4_SwissProt_ID:
Q07982

# Drug_Target_4_SwissProt_Name:
GFO_ZYMMO

# Drug_Target_4_Synonyms:
EC 1.1.99.28
GFOR
Glucose--fructose oxidoreductase precursor

# Drug_Target_4_Theoretical_pI:
8.73

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Secreted protein

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
SERPINA1

# Drug_Target_5_GenBank_ID_Gene:
K01396

# Drug_Target_5_GenBank_ID_Protein:
177829

# Drug_Target_5_GeneCard_ID:
SERPINA1

# Drug_Target_5_Gene_Name:
SERPINA1

# Drug_Target_5_Gene_Sequence:
>1257 bp
ATGCCGTCTTCTGTCTCGTGGGGCATCCTCCTGCTGGCAGGCCTGTGCTGCCTGGTCCCT
GTCTCCCTGGCTGAGGATCCCCAGGGAGATGCTGCCCAGAAGACAGATACATCCCACCAT
GATCAGGATCACCCAACCTTCAACAAGATCACCCCCAACCTGGCTGAGTTCGCCTTCAGC
CTATACCGCCAGCTGGCACACCAGTCCAACAGCACCAATATCTTCTTCTCCCCAGTGAGC
ATCGCTACAGCCTTTGCAATGCTCTCCCTGGGGACCAAGGCTGACACTCACGATGAAATC
CTGGAGGGCCTGAATTTCAACCTCACGGAGATTCCGGAGGCTCAGATCCATGAAGGCTTC
CAGGAACTCCTCCGTACCCTCAACCAGCCAGACAGCCAGCTCCAGCTGACCACCGGCAAT
GGCCTGTTCCTCAGCGAGGGCCTGAAGCTAGTGGATAAGTTTTTGGAGGATGTTAAAAAG
TTGTACCACTCAGAAGCCTTCACTGTCAACTTCGGGGACACCGAAGAGGCCAAGAAACAG
ATCAACGATTACGTGGAGAAGGGTACTCAAGGGAAAATTGTGGATTTGGTCAAGGAGCTT
GACAGAGACACAGTTTTTGCTCTGGTGAATTACATCTTCTTTAAAGGCAAATGGGAGAGA
CCCTTTGAAGTCAAGGACACCGAGGAAGAGGACTTCCACGTGGACCAGGTGACCACCGTG
AAGGTGCCTATGATGAAGCGTTTAGGCATGTTTAACATCCAGCACTGTAAGAAGCTGTCC
AGCTGGGTGCTGCTGATGAAATACCTGGGCAATGCCACCGCCATCTTCTTCCTGCCTGAT
GAGGGGAAACTACAGCACCTGGAAAATGAACTCACCCACGATATCATCACCAAGTTCCTG
GAAAATGAAGACAGAAGGTCTGCCAGCTTACATTTACCCAAACTGTCCATTACTGGAACC
TATGATCTGAAGAGCGTCCTGGGTCAACTGGGCATCACTAAGGTCTTCAGCAATGGGGCT
GACCTCTCCGGGGTCACAGAGGAGGCACCCCTGAAGCTCTCCAAGGCCGTGCATAAGGCT
GTGCTGACCATCGACGAGAAAGGGACTGAAGCTGCTGGGGCCATGTTTTTAGAGGCCATA
CCCATGTCTATCCCCCCCGAGGTCAAGTTCAACAAACCCTTTGTCTTCTTAATGATTGAA
CAAAATACCAAGTCTCCCCTCTTCATGGGAAAAGTGGTGAATCCCACCCAAAAATAA

# Drug_Target_5_General_Function:
Involved in serine-type endopeptidase inhibitor activity

# Drug_Target_5_General_References:
10612848	Seixas S, Garcia O, Amorim A, Rocha J: A novel alpha-1-antitrypsin r281del variant found in a population sample from the Basque country. Hum Mutat. 2000 Jan;15(1):121-2.
10716194	Dunstone MA, Dai W, Whisstock JC, Rossjohn J, Pike RN, Feil SC, Le Bonniec BF, Parker MW, Bottomley SP: Cleaved antitrypsin polymers at atomic resolution. Protein Sci. 2000 Feb;9(2):417-20.
10933492	Elliott PR, Pei XY, Dafforn TR, Lomas DA: Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Sci. 2000 Jul;9(7):1274-81.
11057674	Huntington JA, Read RJ, Carrell RW: Structure of a serpin-protease complex shows inhibition by deformation. Nature. 2000 Oct 19;407(6806):923-6.
11178897	Kim S, Woo J, Seo EJ, Yu M, Ryu S: A 2.1 A resolution structure of an uncleaved alpha(1)-antitrypsin shows variability of the reactive center and other loops. J Mol Biol. 2001 Feb 9;306(1):109-19.
12244055	Im H, Woo MS, Hwang KY, Yu MH: Interactions causing the kinetic trap in serpin protein folding. J Biol Chem. 2002 Nov 29;277(48):46347-54. Epub 2002 Sep 18.
12754519	Zhang H, Li XJ, Martin DB, Aebersold R: Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol. 2003 Jun;21(6):660-6. Epub 2003 May 18.
12860985	Dementiev A, Simonovic M, Volz K, Gettins PG: Canonical inhibitor-like interactions explain reactivity of alpha1-proteinase inhibitor Pittsburgh and antithrombin with proteinases. J Biol Chem. 2003 Sep 26;278(39):37881-7. Epub 2003 Jul 14.
1859394	Wu Y, Foreman RC: The molecular genetics of alpha 1 antitrypsin deficiency. Bioessays. 1991 Apr;13(4):163-9.
1905728	Seyama K, Nukiwa T, Takabe K, Takahashi H, Miyake K, Kira S: Siiyama (serine 53 (TCC) to phenylalanine 53 (TTC)). A new alpha 1-antitrypsin-deficient variant with mutation on a predicted conserved residue of the serpin backbone. J Biol Chem. 1991 Jul 5;266(19):12627-32.
1967187	Curiel DT, Vogelmeier C, Hubbard RC, Stier LE, Crystal RG: Molecular basis of alpha 1-antitrypsin deficiency and emphysema associated with the alpha 1-antitrypsin Mmineral springs allele. Mol Cell Biol. 1990 Jan;10(1):47-56.
2035534	Okayama H, Brantly M, Holmes M, Crystal RG: Characterization of the molecular basis of the alpha 1-antitrypsin F allele. Am J Hum Genet. 1991 Jun;48(6):1154-8.
2227940	Graham A, Kalsheker NA, Bamforth FJ, Newton CR, Markham AF: Molecular characterisation of two alpha-1-antitrypsin deficiency variants: proteinase inhibitor (Pi) Null(Newport) (Gly115----Ser) and (Pi) Z Wrexham (Ser-19----Leu). Hum Genet. 1990 Oct;85(5):537-40.
2254451	Frazier GC, Siewertsen MA, Hofker MH, Brubacher MG, Cox DW: A null deficiency allele of alpha 1-antitrypsin, QOludwigshafen, with altered tertiary structure. J Clin Invest. 1990 Dec;86(6):1878-84.
2309708	Matsunaga E, Shiokawa S, Nakamura H, Maruyama T, Tsuda K, Fukumaki Y: Molecular analysis of the gene of the alpha 1-antitrypsin deficiency variant, Mnichinan. Am J Hum Genet. 1990 Mar;46(3):602-12.
2316526	Holmes MD, Brantly ML, Curiel DT, Weidinger S, Crystal RG: Characterization of the normal alpha 1-antitrypsin allele Vmunich: a variant associated with a unique protein isoelectric focusing pattern. Am J Hum Genet. 1990 Apr;46(4):810-6.
2339709	Faber JP, Weidinger S, Olek K: Sequence data of the rare deficient alpha 1-antitrypsin variant PI Zaugsburg. Am J Hum Genet. 1990 Jun;46(6):1158-62.
2390072	Holmes MD, Brantly ML, Fells GA, Crystal RG: Alpha 1-antitrypsin Wbethesda: molecular basis of an unusual alpha 1-antitrypsin deficiency variant. Biochem Biophys Res Commun. 1990 Aug 16;170(3):1013-20.
2394452	Graham A, Hayes K, Weidinger S, Newton CR, Markham AF, Kalsheker NA: Characterisation of the alpha-1-antitrypsin M3 gene, a normal variant. Hum Genet. 1990 Aug;85(3):381-2.
2606478	Graham A, Kalsheker NA, Newton CR, Bamforth FJ, Powell SJ, Markham AF: Molecular characterisation of three alpha-1-antitrypsin deficiency variants: proteinase inhibitor (Pi) nullcardiff (Asp256----Val); PiMmalton (Phe51----deletion) and PiI (Arg39----Cys). Hum Genet. 1989 Dec;84(1):55-8.
2669992	Kalsheker N: Alpha 1-antitrypsin: structure, function and molecular biology of the gene. Biosci Rep. 1989 Apr;9(2):129-38.
2784123	Hofker MH, Nukiwa T, van Paassen HM, Nelen M, Kramps JA, Klasen EC, Frants RR, Crystal RG: A Pro----Leu substitution in codon 369 of the alpha-1-antitrypsin deficiency variant PI MHeerlen. Hum Genet. 1989 Feb;81(3):264-8.
2785270	Engh R, Lobermann H, Schneider M, Wiegand G, Huber R, Laurell CB: The S variant of human alpha 1-antitrypsin, structure and implications for function and metabolism. Protein Eng. 1989 Mar;2(6):407-15.
2786335	Fraizer GC, Harrold TR, Hofker MH, Cox DW: In-frame single codon deletion in the Mmalton deficiency allele of alpha 1-antitrypsin. Am J Hum Genet. 1989 Jun;44(6):894-902.
2901226	Nukiwa T, Brantly ML, Ogushi F, Fells GA, Crystal RG: Characterization of the gene and protein of the common alpha 1-antitrypsin normal M2 allele. Am J Hum Genet. 1988 Sep;43(3):322-30.
2985281	Ciliberto G, Dente L, Cortese R: Cell-specific expression of a transfected human alpha 1-antitrypsin gene. Cell. 1985 Jun;41(2):531-40.
3262617	Takahashi H, Nukiwa T, Satoh K, Ogushi F, Brantly M, Fells G, Stier L, Courtney M, Crystal RG: Characterization of the gene and protein of the alpha 1-antitrypsin "deficiency" allele Mprocida. J Biol Chem. 1988 Oct 25;263(30):15528-34.
3491072	Nukiwa T, Satoh K, Brantly ML, Ogushi F, Fells GA, Courtney M, Crystal RG: Identification of a second mutation in the protein-coding sequence of the Z type alpha 1-antitrypsin gene. J Biol Chem. 1986 Dec 5;261(34):15989-94.
3873938	Coutelle C, Speer A, Rogers J, Kalsheker N, Humphries S, Williamson R: Construction and partial characterization of a human liver cDNA library. Biomed Biochim Acta. 1985;44(3):421-31.
3876243	Riley JH, Bathurst IC, Edbrooke MR, Carrell RW, Craig RK: Alpha 1-antitrypsin and serum albumin mRNA accumulation in normal, acute phase and ZZ human liver. FEBS Lett. 1985 Sep 23;189(2):361-6.
6093867	Long GL, Chandra T, Woo SL, Davie EW, Kurachi K: Complete sequence of the cDNA for human alpha 1-antitrypsin and the gene for the S variant. Biochemistry. 1984 Oct 9;23(21):4828-37.
6319097	Bollen A, Herzog A, Cravador A, Herion P, Chuchana P, Vander Straten A, Loriau R, Jacobs P, van Elsen A: Cloning and expression in Escherichia coli of full-length complementary DNA coding for human alpha 1-antitrypsin. DNA. 1983;2(4):255-64.
6332197	Loebermann H, Tokuoka R, Deisenhofer J, Huber R: Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J Mol Biol. 1984 Aug 15;177(3):531-57.
6387509	Rosenberg S, Barr PJ, Najarian RC, Hallewell RA: Synthesis in yeast of a functional oxidation-resistant mutant of human alpha-antitrypsin. Nature. 1984 Nov 1-7;312(5989):77-80.
6604220	Owen MC, Brennan SO, Lewis JH, Carrell RW: Mutation of antitrypsin to antithrombin. alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder. N Engl J Med. 1983 Sep 22;309(12):694-8.
6979715	Leicht M, Long GL, Chandra T, Kurachi K, Kidd VJ, Mace M Jr, Davie EW, Woo SL: Sequence homology and structural comparison between the chromosomal human alpha 1-antitrypsin and chicken ovalbumin genes. Nature. 1982 Jun 24;297(5868):655-9.
7031661	Kurachi K, Chandra T, Degen SJ, White TT, Marchioro TL, Woo SL, Davie EW: Cloning and sequence of cDNA coding for alpha 1-antitrypsin. Proc Natl Acad Sci U S A. 1981 Nov;78(11):6826-30.
7045697	Carrell RW, Jeppsson JO, Laurell CB, Brennan SO, Owen MC, Vaughan L, Boswell DR: Structure and variation of human alpha 1-antitrypsin. Nature. 1982 Jul 22;298(5872):329-34.
7977369	Faber JP, Poller W, Weidinger S, Kirchgesser M, Schwaab R, Bidlingmaier F, Olek K: Identification and DNA sequence analysis of 15 new alpha 1-antitrypsin variants, including two PI*Q0 alleles and one deficient PI*M allele. Am J Hum Genet. 1994 Dec;55(6):1113-21.
8364590	Hildesheim J, Kinsley G, Bissell M, Pierce J, Brantly M: Genetic diversity from a limited repertoire of mutations on different common allelic backgrounds: alpha 1-antitrypsin deficiency variant Pduarte. Hum Mutat. 1993;2(3):221-8.
8543039	Song HK, Lee KN, Kwon KS, Yu MH, Suh SW: Crystal structure of an uncleaved alpha 1-antitrypsin reveals the conformation of its inhibitory reactive loop. FEBS Lett. 1995 Dec 18;377(2):150-4.
8756325	Elliott PR, Lomas DA, Carrell RW, Abrahams JP: Inhibitory conformation of the reactive loop of alpha 1-antitrypsin. Nat Struct Biol. 1996 Aug;3(8):676-81.
8939743	Ryu SE, Choi HJ, Kwon KS, Lee KN, Yu MH: The native strains in the hydrophobic core and flexible reactive loop of a serine protease inhibitor: crystal structure of an uncleaved alpha1-antitrypsin at 2.7 A. Structure. 1996 Oct 15;4(10):1181-92.
9459000	Lovegrove JU, Jeremiah S, Gillett GT, Temple IK, Povey S, Whitehouse DB: A new alpha 1-antitrypsin mutation, Thr-Met 85, (PI Zbristol) associated with novel electrophoretic properties. Ann Hum Genet. 1997 Sep;61(Pt 5):385-91.
9466920	Elliott PR, Abrahams JP, Lomas DA: Wild-type alpha 1-antitrypsin is in the canonical inhibitory conformation. J Mol Biol. 1998 Jan 23;275(3):419-25.

# Drug_Target_5_HGNC_ID:
HGNC:8941

# Drug_Target_5_HPRD_ID:
02463

# Drug_Target_5_ID:
1277

# Drug_Target_5_Locus:
14q32.1

# Drug_Target_5_Molecular_Weight:
46737

# Drug_Target_5_Name:
Alpha-1-antitrypsin

# Drug_Target_5_Number_of_Residues:
418

# Drug_Target_5_PDB_ID:
1QLP

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00079	Serpin

# Drug_Target_5_Protein_Sequence:
>Alpha-1-antitrypsin precursor
MPSSVSWGILLLAGLCCLVPVSLAEDPQGDAAQKTDTSHHDQDHPTFNKITPNLAEFAFS
LYRQLAHQSNSTNIFFSPVSIATAFAMLSLGTKADTHDEILEGLNFNLTEIPEAQIHEGF
QELLRTLNQPDSQLQLTTGNGLFLSEGLKLVDKFLEDVKKLYHSEAFTVNFGDTEEAKKQ
INDYVEKGTQGKIVDLVKELDRDTVFALVNYIFFKGKWERPFEVKDTEEEDFHVDQVTTV
KVPMMKRLGMFNIQHCKKLSSWVLLMKYLGNATAIFFLPDEGKLQHLENELTHDIITKFL
ENEDRRSASLHLPKLSITGTYDLKSVLGQLGITKVFSNGADLSGVTEEAPLKLSKAVHKA
VLTIDEKGTEAAGAMFLEAIPMSIPPEVKFNKPFVFLMIEQNTKSPLFMGKVVNPTQK

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
1-24

# Drug_Target_5_Specific_Function:
Inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin

# Drug_Target_5_SwissProt_ID:
P01009

# Drug_Target_5_SwissProt_Name:
A1AT_HUMAN

# Drug_Target_5_Synonyms:
Alpha-1 protease inhibitor
Alpha-1- antiproteinase
Alpha-1-antitrypsin precursor

# Drug_Target_5_Theoretical_pI:
5.31

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Not Available

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
Not Available

# Drug_Target_6_GenBank_ID_Gene:
Not Available

# Drug_Target_6_GenBank_ID_Protein:
Not Available

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
LGALS1

# Drug_Target_6_Gene_Sequence:
Not Available

# Drug_Target_6_General_Function:
Not Available

# Drug_Target_6_General_References:
Not Available

# Drug_Target_6_HGNC_ID:
Not Available

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
7003

# Drug_Target_6_Locus:
Not Available

# Drug_Target_6_Molecular_Weight:
Not Available

# Drug_Target_6_Name:
Galectin-1

# Drug_Target_6_Number_of_Residues:
0

# Drug_Target_6_PDB_ID:
Not Available

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
Not Available

# Drug_Target_6_Protein_Sequence:
Not Available

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
Not Available

# Drug_Target_6_Specific_Function:
Not Available

# Drug_Target_6_SwissProt_ID:
P09382

# Drug_Target_6_SwissProt_Name:
LEG1_HUMAN

# Drug_Target_6_Synonyms:
Not Available

# Drug_Target_6_Theoretical_pI:
Not Available

# Drug_Target_6_Transmembrane_Regions:
Not Available

# Drug_Target_7_Cellular_Location:
Not Available

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
Not Available

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
Not Available

# Drug_Target_7_GenBank_ID_Gene:
J02459

# Drug_Target_7_GenBank_ID_Protein:
Not Available

# Drug_Target_7_GeneCard_ID:
Not Available

# Drug_Target_7_Gene_Name:
ninB

# Drug_Target_7_Gene_Sequence:
>441 bp
ATGAAAAAACTAACCTTTGAAATTCGATCTCCAGCACATCAGCAAAACGCTATTCACGCA
GTACAGCAAATCCTTCCAGACCCAACCAAACCAATCGTAGTAACCATTCAGGAACGCAAC
CGCAGCTTAGACCAAAACAGGAAGCTATGGGCCTGCTTAGGTGACGTCTCTCGTCAGGTT
GAATGGCATGGTCGCTGGCTGGATGCAGAAAGCTGGAAGTGTGTGTTTACCGCAGCATTA
AAGCAGCAGGATGTTGTTCCTAACCTTGCCGGGAATGGCTTTGTGGTAATAGGCCAGTCA
ACCAGCAGGATGCGTGTAGGCGAATTTGCGGAGCTATTAGAGCTTATACAGGCATTCGGT
ACAGAGCGTGGCGTTAAGTGGTCAGACGAAGCGAGACTGGCTCTGGAGTGGAAAGCGAGA
TGGGGAGACAGGGCTGCATGA

# Drug_Target_7_General_Function:
Not Available

# Drug_Target_7_General_References:
6221115	Sanger F, Coulson AR, Hong GF, Hill DF, Petersen GB: Nucleotide sequence of bacteriophage lambda DNA. J Mol Biol. 1982 Dec 25;162(4):729-73.

# Drug_Target_7_HGNC_ID:
Not Available

# Drug_Target_7_HPRD_ID:
Not Available

# Drug_Target_7_ID:
5226

# Drug_Target_7_Locus:
Not Available

# Drug_Target_7_Molecular_Weight:
16648

# Drug_Target_7_Name:
Protein ninB

# Drug_Target_7_Number_of_Residues:
146

# Drug_Target_7_PDB_ID:
1PC6

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF05772	NinB

# Drug_Target_7_Protein_Sequence:
>Protein ninB
MKKLTFEIRSPAHQQNAIHAVQQILPDPTKPIVVTIQERNRSLDQNRKLWACLGDVSRQV
EWHGRWLDAESWKCVFTAALKQQDVVPNLAGNGFVVIGQSTSRMRVGEFAELLELIQAFG
TERGVKWSDEARLALEWKARWGDRAA

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
Not Available

# Drug_Target_7_SwissProt_ID:
P03765

# Drug_Target_7_SwissProt_Name:
NINB_LAMBD

# Drug_Target_7_Synonyms:
Not Available

# Drug_Target_7_Theoretical_pI:
9.44

# Drug_Target_7_Transmembrane_Regions:
None

# Drug_Target_8_Cellular_Location:
Not Available

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
Not Available

# Drug_Target_8_GenBank_ID_Gene:
Not Available

# Drug_Target_8_GenBank_ID_Protein:
Not Available

# Drug_Target_8_GeneCard_ID:
Not Available

# Drug_Target_8_Gene_Name:
SCMH1

# Drug_Target_8_Gene_Sequence:
Not Available

# Drug_Target_8_General_Function:
Not Available

# Drug_Target_8_General_References:
Not Available

# Drug_Target_8_HGNC_ID:
Not Available

# Drug_Target_8_HPRD_ID:
Not Available

# Drug_Target_8_ID:
7147

# Drug_Target_8_Locus:
Not Available

# Drug_Target_8_Molecular_Weight:
Not Available

# Drug_Target_8_Name:
Polycomb protein SCMH1

# Drug_Target_8_Number_of_Residues:
0

# Drug_Target_8_PDB_ID:
Not Available

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
Not Available

# Drug_Target_8_Protein_Sequence:
Not Available

# Drug_Target_8_Reaction:
Not Available

# Drug_Target_8_Signals:
Not Available

# Drug_Target_8_Specific_Function:
Not Available

# Drug_Target_8_SwissProt_ID:
Q96GD3

# Drug_Target_8_SwissProt_Name:
SCMH1_HUMAN

# Drug_Target_8_Synonyms:
Not Available

# Drug_Target_8_Theoretical_pI:
Not Available

# Drug_Target_8_Transmembrane_Regions:
Not Available

# Drug_Target_9_Cellular_Location:
Not Available

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
Not Available

# Drug_Target_9_GenBank_ID_Gene:
M92351

# Drug_Target_9_GenBank_ID_Protein:
Not Available

# Drug_Target_9_GeneCard_ID:
Not Available

# Drug_Target_9_Gene_Name:
pdxH

# Drug_Target_9_Gene_Sequence:
Not Available

# Drug_Target_9_General_Function:
Coenzyme transport and metabolism

# Drug_Target_9_General_References:
10903950	Safo MK, Mathews I, Musayev FN, di Salvo ML, Thiel DJ, Abraham DJ, Schirch V: X-ray structure of Escherichia coli pyridoxine 5'-phosphate oxidase complexed with FMN at 1.8 A resolution. Structure. 2000 Jul 15;8(7):751-62.
11453690	Safo MK, Musayev FN, di Salvo ML, Schirch V: X-ray structure of Escherichia coli pyridoxine 5'-phosphate oxidase complexed with pyridoxal 5'-phosphate at 2.0 A resolution. J Mol Biol. 2001 Jul 20;310(4):817-26.
1356963	Lam HM, Winkler ME: Characterization of the complex pdxH-tyrS operon of Escherichia coli K-12 and pleiotropic phenotypes caused by pdxH insertion mutations. J Bacteriol. 1992 Oct;174(19):6033-45.
7860596	Zhao G, Winkler ME: Kinetic limitation and cellular amount of pyridoxine (pyridoxamine) 5'-phosphate oxidase of Escherichia coli K-12. J Bacteriol. 1995 Feb;177(4):883-91.
9097039	Aiba H, Baba T, Hayashi K, Inada T, Isono K, Itoh T, Kasai H, Kashimoto K, Kimura S, Kitakawa M, Kitagawa M, Makino K, Miki T, Mizobuchi K, Mori H, Mori T, Motomura K, Nakade S, Nakamura Y, Nashimoto H, Nishio Y, Oshima T, Saito N, Sampei G, Horiuchi T, et al.: A 570-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 28.0-40.1 min region on the linkage map. DNA Res. 1996 Dec 31;3(6):363-77.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9693059	Di Salvo M, Yang E, Zhao G, Winkler ME, Schirch V: Expression, purification, and characterization of recombinant Escherichia coli pyridoxine 5'-phosphate oxidase. Protein Expr Purif. 1998 Aug;13(3):349-56.

# Drug_Target_9_HGNC_ID:
Not Available

# Drug_Target_9_HPRD_ID:
Not Available

# Drug_Target_9_ID:
3766

# Drug_Target_9_Locus:
Not Available

# Drug_Target_9_Molecular_Weight:
25545

# Drug_Target_9_Name:
Pyridoxamine 5'-phosphate oxidase

# Drug_Target_9_Number_of_Residues:
218

# Drug_Target_9_PDB_ID:
1WV4

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF01243	Pyridox_oxidase

# Drug_Target_9_Protein_Sequence:
>Pyridoxamine 5'-phosphate oxidase
MSDNDELQQIAHLRREYTKGGLRRRDLPADPLTLFERWLSQACEAKLADPTAMVVATVDE
HGQPYQRIVLLKHYDEKGMVFYTNLGSRKAHQIENNPRVSLLFPWHTLERQVMVIGKAER
LSTLEVMKYFHSRPRDSQIGAWVSKQSSRISARGILESKFLELKQKFQQGEVPLPSFWGG
FRVSLEQIEFWQGGEHRLHDRFLYQRENDAWKIDRLAP

# Drug_Target_9_Reaction:
pyridoxamine 5'-phosphate + H2O + O2 = pyridoxal 5'-phosphate + ammonia + H2O2

# Drug_Target_9_Signals:
None

# Drug_Target_9_Specific_Function:
Oxidizes PNP and PMP into pyridoxal 5'-phosphate (PLP)

# Drug_Target_9_SwissProt_ID:
P0AFI7

# Drug_Target_9_SwissProt_Name:
PDXH_ECOLI

# Drug_Target_9_Synonyms:
EC 1.4.3.5
PNP/PMP oxidase
PNPOx

# Drug_Target_9_Theoretical_pI:
9.60

# Drug_Target_9_Transmembrane_Regions:
None

#END_DRUGCARD DB03345
